Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study

Not Applicable

Completed

• Conditions: Risk Reduction; HIV Infections; Risk Behavior; HIV Infection Primary; Risky Health Behavior; STD; HIV Seropositivity
• Interventions: Procedure: HIV testing

• Registration Number: NCT05674682
• Lead Sponsor: Evandro Chagas National Institute of Infectious Disease

Brief Summary

PrEP (pre-exposure prophylaxis) is an effective prevention strategy in which HIV-negative individuals take antiretroviral drugs (tenofovir disoproxil fumarate and emtricitabine - TDF/FTC) to reduce HIV acquisition. Clinical studies have shown that the TDF/FTC combination protects MSM and transgender women against HIV infection. According to the PROUD study, PrEP can decrease the risk of HIV infection among MSM by 86% (90% CI 64-96). The international community recognizes that PrEP can be an additional tool in the framework of a combination prevention package for those most at risk of contracting HIV. Data on HIV incidence among MSM and trans women are largely unknown. In Brazil, Mexico and Peru, data on the incidence of HIV among MSM and trans women are very scarce, limited to small cross-sectional studies.Current methods used to determine HIV-1 incidence have many limitations. These methods include mathematical modeling, retrospective calculations of AIDS case reports, age-based prevalence determinations, and prevalence determinations with multiple rounds of longitudinal surveys to estimate HIV incidence, which require numerous assumptions and inputs and can pose additional challenges in the era of expansion of antiretroviral therapy (ART) and increased survival of HIV-1 infected individuals. On the other hand, prospective longitudinal cohort studies of high-risk individuals can be used to estimate incidence; however, they are often labor-intensive, complex, very expensive, difficult to implement in most countries, and have recruitment biases. Laboratory methods can be unbiased and do not require complicated assumptions and case-by-case weighting. The cross-sectional use of Recent HIV Infection Tests (TRIs) based on biomarkers offers, in principle, accessible, reliable and low risk of bias options for estimating incidence.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-10-01
• Primary Completion: 2020-05-31
• Study Completion: 2020-06-30
• Status Verified: 2023-01
• Study First Submitted: 2023-01-03
• Study First Submitted QC: 2023-01-05
• Last Update Submitted: 2023-01-05
• Study First Posted: 2023-01-06
• Last Update Posted: 2023-01-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 4000

Inclusion Criteria

• MSM and transgender women
• aged 18 years or older
• willingness and ability to sign an informed consent form.

Exclusion Criteria

• Individuals currently using PrEP, PEP or receiving antiretroviral therapy;
• Individuals unable to understand the study or who do not agree to sign the consent form;
• Individuals who are participating in a clinical trial of antiretroviral medication or any investigational product to prevent the acquisition of HIV infection (for example, monoclonal antibodies such as PEP or PrEP)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Venipuncture or digital puncture for HIV test	HIV testing	MSM and transgender women aged 18 years or older, willing and able to sign informed consent to accept venipuncture or digital puncture for HIV testing

Primary Outcome Measures

Name	Time	Method
Identification of recent infections in a given high-risk population (MSM and TGW), including those in defined geographic areas for evaluate epidemics, calibrate models, design and evaluate interventions.	2 years	Blood collected for viral load from those with confirmed HIV infection will be used to distinguish recent HIV-1 infections of long-term infections

Trial Locations

Locations (2)

Instituto Nacional de Infectologia Evandro Chagas (Fiocruz); 🇧🇷 Rio de Janeiro, RJ, Brazil

Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ; 🇧🇷 Rio De Janeiro, Brazil